Revvity’s first quarter results were well received by the market, as the company delivered stronger-than-expected organic growth and margins. Management attributed the positive performance to solid execution in both the Life Sciences and Diagnostics segments, with particular momentum in reagents, instruments, and reproductive health. CEO Prahlad Singh highlighted that “the better-than-anticipated revenue and margin performance” reflected resilience across key customer groups, including pharma, biotech, and academic institutions. Strong demand for high-content screening and recent software launches also contributed to the quarter’s results.
Is now the time to buy RVTY? Find out in our full research report (it’s free for active Edge members).
Revvity (RVTY) Q1 CY2026 Highlights:
- Revenue: $686.9 million vs analyst estimates of $705.1 million (9.3% year-on-year growth, 2.6% miss)
- Adjusted EPS: $1.06 vs analyst estimates of $1.01 (4.5% beat)
- Adjusted EBITDA: $270.1 million vs analyst estimates of $182.5 million (39.3% margin, 48% beat)
- The company dropped its revenue guidance for the full year to $2.83 billion at the midpoint from $2.98 billion, a 5% decrease
- Management lowered its full-year Adjusted EPS guidance to $5.25 at the midpoint, a 2.8% decrease
- Operating Margin: 11.7%, up from 3.2% in the same quarter last year
- Organic Revenue rose 3% year on year (beat)
- Market Capitalization: $11.06 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Revvity’s Q1 Earnings Call
- Patrick Donnelly (Citi): Asked about customer engagement and growth cadence in software. CEO Prahlad Singh emphasized strong interest in new AI-powered platforms, while CFO Max Krakowiak explained that tough comparisons will impact near-term growth but expects acceleration later in the year.
- Puneet Souda (Leerink): Questioned how the China divestiture affects M&A appetite. Singh said Revvity remains acquisitive but will focus capital on high-return opportunities and share buybacks, rather than large-scale deals.
- Daniel Brennan (TD Cowen): Inquired about drivers of strength in reproductive health and the outlook for the Genomics England contract. Krakowiak highlighted robust instrument placements and assay expansion, noting the business should remain resilient despite birth rate pressures.
- Michael Ryskin (BofA): Sought clarity on the long-term margin impact of the China divestiture. Singh and Krakowiak stated that the margin uplift is intended to be permanent, establishing a new baseline for future years.
- Tycho Peterson (Jefferies): Asked about signs of a turnaround in biopharma demand. Singh said improvements are visible but gradual, with a cautious outlook until more consistent positive trends emerge.
Catalysts in Upcoming Quarters
Over the next few quarters, the StockStory team will be monitoring (1) progress toward closing the China immunodiagnostics divestiture and its impact on reported financials, (2) adoption rates for new AI-driven software and instrument launches, and (3) evidence of sustained recovery in pharma, biotech, and academic customer demand. Execution on operational efficiency programs and further updates on capital deployment will also be closely watched.
Revvity currently trades at $98.96, up from $86.51 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
